ReviewStem cells translational medicine2017
Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access.
Review in Stem cells translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Treatment-related neuroanatomical and functional consequences of hematopoietic stem cell transplantation: A comprehensive review of brain structure and function.Chinese medical journal · 2026Review
- Translational Progress and Clinical Challenges in Bioengineered Bone and Joint Repair.Biomedicines · 2026Review
- Innovative Contracting for Gene Therapies: Current Landscape and Perspectives on the Future of Gene Therapy Financing in the USA.PharmacoEconomics · 2026Review
- Article
- A Scoping Review of Precision Medicine in Breast Reconstruction (2011-2025).Journal of personalized medicine · 2025Review
- Enabling Mesenchymal Stromal Cells and Their Extracellular Vesicles Clinical Availability-A Technological and Economical Evaluation.Journal of extracellular biology · 2025Article
- Development of Functional Recovery Therapy for Post-Stroke Sequelae: Towards a Future without Stroke Aftereffects.Juntendo medical journal · 2025Article
- Advancing the Battle against Cystic Fibrosis: Stem Cell and Gene Therapy Insights.Current medical science · 2024Review
- Barriers to accessing cellular therapy for patients receiving care in community practices.Hematology. American Society of Hematology. Education Program · 2023Article
- A Combined Western and Bead-Based Multiplex Platform to Characterize Extracellular Vesicles.Tissue engineering. Part C, Methods · 2023Article
- Clinical use of autologous cell-based therapies in an evolving regulatory landscape: A survey of patient experiences and perceptions.F1000Research · 2023Article
- Promoting endogenous articular cartilage regeneration using extracellular matrix scaffolds.Materials today. Bio · 2022Article
- Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.The European journal of health economics : HEPAC : health economics in prevention and care · 2022Article
- Longevity leap: mind the healthspan gap.NPJ Regenerative medicine · 2021Review
- Regenerative medicine clinical readiness.Regenerative medicine · 2021Review
- Racial disparities in hematopoietic stem cell transplant: a systematic review of the literature.Stem cell investigation · 2021Review
- Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland.Frontiers in public health · 2021Review
- Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers.Frontiers in public health · 2021Review
- Hurdles to uptake of mesenchymal stem cells and their progenitors in therapeutic products.The Biochemical journal · 2020Review
- Extracellular Vesicles Mediate Neuroprotection and Functional Recovery after Traumatic Brain Injury.Journal of neurotrauma · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular therapies and other regenerative medicines are emerging as potentially transformative additions to modern medicine, but likely at a staggering financial cost. Public health care systems' budgets are already strained by growing and aging populations, and many private insurer's budgets are equally stretched. The current systems that most payers employ to manage their cash flow are not structured to absorb a sudden onslaught of very expensive prescriptions for a large portion of their covered population. Despite this, developers of new regenerative medicines tend to focus on the demands of regulators, not payers, in order to be compliant throughout the clinical trials phases, and to develop a product that ultimately will be approvable. It is not advisable to assume that an approved product will automatically become a reimbursed product, as examples from current practice in hematopoietic stem cell transplantation in the U.S. demonstrate; similarly, in Europe numerous Advanced-therapy Medicinal Products achieved market authorization but failed to secure reimbursement (e.g., Glybera, Provenge, ChondroCelect, MACI). There are however strategies and approaches that developers can employ throughout clinical development, in order to generate clinical and health economic data which will be necessary to demonstrate the value proposition of the new product and help ensure market access for patients; furthermore, performance based managed entry agreements coupled with post-launch evidence generation can help overcome challenges around product uncertainty at launch and reduce market access delays. Stem Cells Translational Medicine 2017;6:1723-1729.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.